124 related articles for article (PubMed ID: 33351511)
1. Ovarian Inflammation Mass Mimicking Recurrent Rectal Cancer 17 Years After Surgery: PET/CT and MRI Findings.
Shen G; Kuang A
Clin Nucl Med; 2021 Sep; 46(9):781-782. PubMed ID: 33351511
[TBL] [Abstract][Full Text] [Related]
2. FDG-avid presacral soft tissue mass in previously treated rectal cancer: Diagnostic outcome and additional value of MRI, including diffusion-weighted imaging.
Pennings JP; de Haas RJ; Murshid KJA; de Jong KP; Dierckx RAJO; Kwee TC
Eur J Surg Oncol; 2019 Apr; 45(4):606-612. PubMed ID: 30594404
[TBL] [Abstract][Full Text] [Related]
3. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
Kim CK; Park BK; Choi JY; Kim BG; Han H
J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
[TBL] [Abstract][Full Text] [Related]
4. The Role of FDG Positron Emission Tomography/Contrast--Enhanced Computed Tomography in Preoperative Staging and Postoperative Follow-up in Rectal Cancer Surgery.
Omarov N; Uymaz DS; Kulle CB; Ozkan ZG; Azamat S; Keskin M; Bulut MT
Pol Przegl Chir; 2022 Feb; 94(6):10-16. PubMed ID: 36468505
[TBL] [Abstract][Full Text] [Related]
5. Recurrent Ovarian Cancer Presenting as a Solitary Chest Wall Metastasis Revealed by FDG PET/CT.
Shen G; Kuang A
Clin Nucl Med; 2022 Apr; 47(4):365-366. PubMed ID: 35143461
[TBL] [Abstract][Full Text] [Related]
6. Beware of False-Positive FDG PET/CT Interpretations for Presacral Recurrent Rectal Cancer.
Pennings JP; de Haas RJ; de Jong KP; Dierckx RAJO; Kwee TC
Clin Nucl Med; 2019 May; 44(5):e342-e344. PubMed ID: 30888991
[TBL] [Abstract][Full Text] [Related]
7. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis of the postoperative local recurrence of rectal cancer by FDG-PET--a case report].
Katsumoto Y; Maruyama N; Nakamura M; Shingai T; Maruyama K; Nakaguchi K; Furukawa J; Okajima S; Sue F; Fukunaga H; Ikenaga M; Sekimoto K
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1688-91. PubMed ID: 11708010
[TBL] [Abstract][Full Text] [Related]
9. The efficiency of
Uemura M; Ikeda M; Handa R; Danno K; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Doki Y; Eguchi H
BMC Cancer; 2021 Oct; 21(1):1132. PubMed ID: 34674666
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences.
Plodeck V; Rahbari NN; Weitz J; Radosa CG; Laniado M; Hoffmann RT; Zöphel K; Beuthien-Baumann B; Kotzerke J; van den Hoff J; Platzek I
Eur Radiol; 2019 Jan; 29(1):422-428. PubMed ID: 29980927
[TBL] [Abstract][Full Text] [Related]
11. Rectal lymph node metastasis in recurrent ovarian carcinoma: essential role of 18F-FDG PET/CT in treatment planning.
Kumagai K; Okamura T; Toyoda M; Senzaki H; Watanabe C; Ohmichi M
World J Surg Oncol; 2013 Aug; 11(1):184. PubMed ID: 23938043
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of fusion images using (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography in local recurrence of rectal cancer.
Fukunaga H; Sekimoto M; Tatsumi M; Ikenaga M; Ohue M; Seshimo I; Higuchi I; Takayama O; Yasui M; Ikeda M; Yamamoto H; Monden M
Int J Oncol; 2002 Apr; 20(4):691-5. PubMed ID: 11894111
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of
Hotta M; Minamimoto R; Yano H; Gohda Y; Shuno Y
Cancer Imaging; 2018 Jan; 18(1):4. PubMed ID: 29378659
[TBL] [Abstract][Full Text] [Related]
16. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
18. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma.
Kubik-Huch RA; Dörffler W; von Schulthess GK; Marincek B; Köchli OR; Seifert B; Haller U; Steinert HC
Eur Radiol; 2000; 10(5):761-7. PubMed ID: 10823629
[TBL] [Abstract][Full Text] [Related]
19. [The value of positron emission tomography in the diagnosis of recurrent rectal cancer].
Lehner B; Schlag P; Strauss L; Dimitrakopoulou A; Herfarth C
Zentralbl Chir; 1990; 115(13):813-7. PubMed ID: 2238957
[TBL] [Abstract][Full Text] [Related]
20. [Imaging modalities in the assessment of presacral recurrent rectal cancer].
Wang Y; Yang S
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 May; 23(5):456-460. PubMed ID: 32842424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
